Does systemic inflammation increase hepatic SHBG production?

While systemic inflammation significantly alters hepatic protein synthesis, the evidence consistently shows that this process results in a decrease rather than an increase in sex hormone-binding globulin (SHBG) production. SHBG is recognized as a negative acute-phase reactant, meaning its synthesis is suppressed during inflammatory states.

Mechanistic insights

The reduction of SHBG during systemic inflammation is driven by the suppression of key transcriptional regulators in the liver.

• HNF-4α Inhibition: Hepatocyte nuclear factor-4α (HNF-4α) is the primary transcriptional driver of the SHBG gene. Pro-inflammatory cytokines, specifically TNF-α and IL-1β, reduce the levels of HNF-4α in hepatocytes.
• Signaling Pathways: TNF-α activates the NF-κB pathway, which leads to a decrease in HNF-4α mRNA and protein expression. Similarly, IL-1β triggers the MAPK (MEK1/2 and JNK) signaling pathways, further downregulating HNF-4α and subsequently reducing SHBG synthesis.
• Gene Suppression: Because the SHBG promoter is highly responsive to HNF-4α, the inflammatory suppression of this transcription factor directly leads to a significant reduction in SHBG output.

Clinical evidence

Research involving human cohorts and cell models supports the inverse relationship between inflammation and SHBG.

• Biomarker Correlation: Clinical studies consistently demonstrate that elevated markers of systemic inflammation, such as C-reactive protein (CRP), are associated with lower serum SHBG levels. For instance, in women, high-sensitivity CRP is inversely correlated with SHBG regardless of BMI.
• Metabolic Context: In conditions characterized by chronic low-grade inflammation, such as obesity and type 2 diabetes, SHBG levels are characteristically low. Experimental models using human SHBG transgenic mice have confirmed that inducing inflammation (e.g., via LPS administration) rapidly suppresses SHBG expression.

Bottom line

Systemic inflammation does not increase SHBG; instead, it acts as a potent suppressor of its production. Inflammatory cytokines like TNF-α and IL-1β downregulate the essential transcription factor HNF-4α, positioning SHBG as a negative acute-phase reactant. For a 36-year-old female, elevated inflammation would likely be associated with lower, not higher, SHBG levels.